The CBX family, for example, CBX4 has been shown to affect the resistance of hepatocellular carcinoma cells to sorafenib [53], the effect of other members on resistance needs to be further investigated, and these may be research directions to explain the development of drug resistance in DLBCL patients. This evidence concerns the gene CBX1 and diffuse large B-cell lymphoma.